Literature DB >> 15699464

Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice.

Trinity Vera1, Montoya Taylor, Quinn Bohman, Averia Flasch, Richard J Roman, David E Stec.   

Abstract

Previous studies have indicated that the production of 20-hydroxyecisatatraenoic acid (20-HETE) is similar in the liver of C57/B6 mice and rats, but the renal production of 20-HETE is very low in this strain of mice. The present study examined the effects of induction of the renal production of 20-HETE with fenofibrate (FF) on the development of angiotensin II (Ang II)-dependent hypertension in C57BL/6J mice. The mice were divided into 4 groups and treated with vehicle (control), FF (90 mg/kg per day, IP), Ang II (1000 ng/kg per minute, SC), and Ang II plus FF. Mean arterial blood pressure (MAP) averaged 109+/-4 and 106+/-2 mm Hg in control and FF-treated mice (n=7). MAP was significantly increased in the Ang II-treated mice to 144+/-4 mm Hg (n=7). However, FF treatment prevented the development of Ang II-dependent hypertension, with MAP averaging 115+/-5 mm Hg in mice treated with both Ang II plus FF (n=7). Renal production of 20-HETE was very low in control (n=7) and Ang II-treated (n=7) mice and was increased by >2-fold in FF-treated (n=7) and Ang II plus FF-treated (n=7) mice. The levels of Cyp4A proteins were markedly increased in the kidneys of mice treated with FF and Ang II plus FF but not in the renal vasculature. These results suggest that upregulation of the production of 20-HETE in renal tubules may contribute to the blood pressure-lowering effects of FF treatment in Ang II-dependent hypertension in C57BL/6J mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699464     DOI: 10.1161/01.HYP.0000153317.06072.2e

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation.

Authors:  Dominik N Muller; Cosima Schmidt; Eduardo Barbosa-Sicard; Maren Wellner; Volkmar Gross; Hantz Hercule; Marija Markovic; Horst Honeck; Friedrich C Luft; Wolf-Hagen Schunck
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

Review 2.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

Review 3.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

4.  PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.

Authors:  Zivar Yousefipour; Mohammad Newaz
Journal:  Acta Pharmacol Sin       Date:  2014-02-24       Impact factor: 6.150

5.  Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.

Authors:  Saifudeen Ismael; Sreeja Purushothaman; V S Harikrishnan; R Renuka Nair
Journal:  Mol Cell Biochem       Date:  2015-05-15       Impact factor: 3.396

6.  20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension.

Authors:  John D Imig
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

Review 7.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

Review 8.  Bilirubin, a Cardiometabolic Signaling Molecule.

Authors:  Terry D Hinds; David E Stec
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

9.  Antihypertensive actions of moderate hyperbilirubinemia: role of superoxide inhibition.

Authors:  David E Stec; Megan V Storm; Brandon E Pruett; Monette U Gousset
Journal:  Am J Hypertens       Date:  2013-03-12       Impact factor: 2.689

10.  Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.

Authors:  Yiqiang Zhou; Pengcheng Luo; Hsin-Hsin Chang; Hui Huang; Tianxin Yang; Zheng Dong; Cong-Yi Wang; Mong-Heng Wang
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.